Prophylaxis Strategies in Hereditary Angioedema Weighing the Evidence

This program will include a discussion of investigational agents not yet approved by the FDA for use in the United States. There will also be a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Hereditary Angioedema Due to C1-INH Deficiency

Short-Term Prophylaxis Treatment Options for Patients With HAE

Need for On-Demand Treatment With Short-Term Prophylaxis

Decision to Use Long-Term Prophylaxis

Long-Term Prophylaxis Attenuated Androgens

Physician Survey on Current Trends in Long-Term HAE Prophylaxis Use

Long-Term Prophylaxis Plasma-Derived C1-INH Concentrate*

Long-Term Prophylaxis Plasma-Derived C1-INH Concentrate

Frequency of Peripheral Vein Difficulties Over Past 6 Months

Long-Term Prophylaxis Antifibrinolytic Agents

Individualizing Treatment Plans for Patients Who Have HAE

COMPACT Study Number of HAE Attacks per Month

COMPACT Study Secondary Endpoints and AEs

Abstracts from AAAAI 2017

Emerging Agents for Prophylactic Use*

Ongoing Preclinical Research*

Concluding Remarks

Abbreviations